Jazz Pharmaceuticals' Ziihera plus chemotherapy cuts death risk 24% in Phase 3 gastroesophageal cancer trial

Bitget2026/10/23 14:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jazz Pharmaceuticals presented updated Phase 3 Ziihera survival results in first-line HER2-positive advanced gastroesophageal adenocarcinoma at ESMO 2026.
Ziihera with chemotherapy significantly improved overall survival versus trastuzumab with chemotherapy.
Adding tislelizumab sustained survival benefits versus trastuzumab with chemotherapy, but did not significantly improve survival over Ziihera with chemotherapy.
Safety profiles remained unchanged with longer follow-up.
The FDA cleared both Ziihera regimens on August 25, 2026, for first-line treatment in specified HER2-positive patient groups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610231015PR_NEWS_USPR_____SF78826) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Jazz Pharmaceuticals' Ziihera plus chemotherapy cuts death risk 24% in Phase 3 gastroesophageal cancer trial

You may also like

Crypto prices